K

Knotus Co Ltd
KOSDAQ:278650

Watchlist Manager
Knotus Co Ltd
KOSDAQ:278650
Watchlist
Price: 1 971 KRW -0.45% Market Closed
Market Cap: 170.9B KRW
Have any thoughts about
Knotus Co Ltd?
Write Note

Knotus Co Ltd
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Knotus Co Ltd
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
K
Knotus Co Ltd
KOSDAQ:278650
Net Income (Common)
-â‚©164m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Samsung Biologics Co Ltd
KRX:207940
Net Income (Common)
â‚©1.1T
CAGR 3-Years
37%
CAGR 5-Years
27%
CAGR 10-Years
N/A
S
ST Pharm Co Ltd
KOSDAQ:237690
Net Income (Common)
â‚©32.4B
CAGR 3-Years
104%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
F
FutureChem Co Ltd
KOSDAQ:220100
Net Income (Common)
-â‚©10.6B
CAGR 3-Years
13%
CAGR 5-Years
1%
CAGR 10-Years
N/A
L
LegoChem Biosciences Inc
KOSDAQ:141080
Net Income (Common)
-â‚©2.9B
CAGR 3-Years
58%
CAGR 5-Years
-22%
CAGR 10-Years
9%
C
Cellivery Therapeutics Inc
KOSDAQ:268600
Net Income (Common)
-â‚©6.1B
CAGR 3-Years
37%
CAGR 5-Years
21%
CAGR 10-Years
N/A
No Stocks Found

Knotus Co Ltd
Glance View

Market Cap
165.9B KRW
Industry
Life Sciences Tools & Services

KNOTUS Co. Ltd. engages in the provision of clinical research services. The company is headquartered in Incheon, Incheon. The company went IPO on 2019-11-27. is a Korea-based company principally engaged in the nonclinical experiment business. Along with subsidiaries, the Company operates its business through three segments. The Nonclinical Contract Research Organization (CRO) Business segment conducts nonclinical experiments on new developed substances such as new drugs, and tests the efficacy and pharmacodynamics of the substances. This segment also provides services including new drug development related equipment, software and analysis of experimental results. The Animal Laboratory Construction Business segment is engaged in the construction and design of animal laboratories and the supply of reagent consumables. The Pet Business segment is engaged in the development of animal medicines and the sale of pet supplies.

Intrinsic Value
2 368.99 KRW
Undervaluation 17%
Intrinsic Value
Price
K

See Also

What is Knotus Co Ltd's Net Income (Common)?
Net Income (Common)
-164m KRW

Based on the financial report for Dec 31, 2023, Knotus Co Ltd's Net Income (Common) amounts to -164m KRW.

What is Knotus Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 1Y
84%

Over the last year, the Net Income (Common) growth was 84%.

Back to Top